Most patients treated with crizotinib experience a relapse within 1–2 years, and around 20–30% of ALK-positive NSCLC patients have brain metastases at diagnosis, with the incidence increasing up to 50% during cancer progression [28]. This evidence concerns the gene ALK and non-small cell lung carcinoma.